205 research outputs found
Supporting data in ENDNOTE for: focused ultrasound transiently increases membrane conductance in isolated crayfish axon
NSF (#1707865, PI – Okada
Low alanine aminotransferase and higher cardiovascular events in type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Aims Non-alcoholic fatty liver disease (NAFLD) is common in type 2 diabetes and associated with higher risk of cardiovascular disease. This study aimed to determine whether alanine aminotransferase (ALT) or gamma-glutamyltransferase (GGT), as markers of liver health and NAFLD, might predict cardiovascular events in this population. Methods Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study were analysed to examine the relationship between liver enzymes and incident cardiovascular events (nonfatal myocardial infarction, stroke, coronary and other cardiovascular death, coronary or carotid revascularization) over 5 years. Results ALT had a linear inverse relationship with the first cardiovascular event on study. After adjustment, for every standard deviation higher baseline ALT (13.2U/L), the risk of an event was 7%(95%CI 4–13, P=0.02) lower. Participants with ALT below and above the reference range 8–41 U/L for women and 9–59 U/L for men, had a hazard ratio of an event of 1.86(95%CI, 1.12–3.09) and 0.65(95%CI, 0.49–0.87), respectively (P=0.001). No relationship was found for GGT. Conclusions The data may indicate that in type 2 diabetes — associated with higher ALT due to prevalent NAFLD — lower ALT is a marker of hepatic or systemic frailty rather than health
The genetics of the Lp antigen
The frequency distribution of the quantitative activity of the Lp antigen was found to be bimodal. It is hypothesized that a major genetic factor is operating to determine the modes.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66117/1/j.1469-1809.1974.tb01991.x.pd
Studies on the heterogeneity of human serum Lp lipoproteins and on the occurrence of double Lp lipoprotein variants
Lp lipoproteins have been prepared by a mild method from the serum of a large number of individuals. Approximately 25% of the individuals tested showed the presence of a double Lp peak in analytical ultracentrifuge diagrams. These double peaks were designated Lp(a)-1 and Lp(a)-2 to distinguish them from the single Lp(a) peak. The mean viscosity-corrected sedimentation coefficient, S 1.004, 20 C and density of the single Lp(a) peak were 15.8±1.8 s ( n =32) and 1.076±0.01 g/ml, of the Lp(a)-1 peak were 13.5±1.1 s ( n =14) and 1.064±0.007 g/ml, and of the Lp(a)-2 peak were 16.8±1.7 s ( n =14) and 1.074±0.009 g/ml. Absorption tests using a double and single Lp preparation showed that both Lp peaks in the double variants possess Lp(a) specificity. Evidence is lacking as yet for individual specificities for either Lp(a)-1 or Lp(a)-2. Interand intra-individual heterogeneity among Lp lipoproteins is discussed.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44186/1/10528_2004_Article_BF00485737.pd
Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice
Plasma phospholipid transfer protein (PLTP) transfers phospholipids
between lipoprotein particles and alters high density lipoprotein (HDL)
subfraction patterns in vitro, but its physiological function is poorly
understood. Transgenic mice that overexpress human PLTP were generated.
Compared with wild-type mice, these mice show a 2.5- to 4.5-fold increase
in PLTP activity in plasma. This results in a 30% to 40% decrease of
plasma levels of HDL cholesterol. Incubation of plasma from transgenic
animals at 37 degrees C reveals a 2- to 3-fold increase in the formation
of pre-beta-HDL compared with plasma from wild-type mice. Although
pre-beta-HDL is normally a minor subfraction of HDL, it is known to be a
very efficient acceptor of peripheral cell cholesterol and a key mediator
in reverse cholesterol transport. Further experiments show that plasma
from transgenic animals is much more efficient in preventing the
accumulation of intracellular cholesterol in macrophages than plasma from
wild-type mice, despite lower total HDL concentrations. It is concluded
that PLTP can act as an antiatherogenic factor preventing cellular
cholesterol overload by generation of pre-beta-HDL
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Aims Reported associations between liver enzymes and mortality may not hold true in type 2 diabetes, owing to a high prevalence of non-alcoholic fatty liver disease, which has been linked to cardiovascular disease and mortality in its own right. Our study aimed to determine whether alanine aminotransferase (ALT) or γ-glutamyl transferase (GGT) levels predict mortality in type 2 diabetes, and to examine possible mechanisms. Methods Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study were analysed to examine the relationship between liver enzymes and all-cause and cause-specific mortality over 5 years. Results Over 5 years, 679 (6.9%) individuals died. After adjustment, for every standard deviation increase in ALT (13.2U/L), the HR for death on study was 0.85 (95% CI 0.78-0.93), p70 U/L, compared with GGT ≤70 U/L, had HR 1.82 (1.48−2.24), p70 U/L was associated with higher risks of death due to cardiovascular disease, cancer and non-cancer/non-cardiovascular causes. The relationship for ALT persisted after adjustment for indirect measures of frailty but was attenuated by elevated hsCRP. Conclusions As in the general population, ALT has a negative, and GGT a positive, correlation with mortality in type 2 diabetes when ALT is less than two times the upper limit of normal. The relationship 4 for ALT appears specific for death due to cardiovascular disease. Links of low ALT with frailty, as a potential mechanism for relationships seen, were neither supported nor conclusively refuted by our analysis and other factors are also likely to be important in those with type 2 diabetes
Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice
Statistical Theory of Spin Relaxation and Diffusion in Solids
A comprehensive theoretical description is given for the spin relaxation and
diffusion in solids. The formulation is made in a general
statistical-mechanical way. The method of the nonequilibrium statistical
operator (NSO) developed by D. N. Zubarev is employed to analyze a relaxation
dynamics of a spin subsystem. Perturbation of this subsystem in solids may
produce a nonequilibrium state which is then relaxed to an equilibrium state
due to the interaction between the particles or with a thermal bath (lattice).
The generalized kinetic equations were derived previously for a system weakly
coupled to a thermal bath to elucidate the nature of transport and relaxation
processes. In this paper, these results are used to describe the relaxation and
diffusion of nuclear spins in solids. The aim is to formulate a successive and
coherent microscopic description of the nuclear magnetic relaxation and
diffusion in solids. The nuclear spin-lattice relaxation is considered and the
Gorter relation is derived. As an example, a theory of spin diffusion of the
nuclear magnetic moment in dilute alloys (like Cu-Mn) is developed. It is shown
that due to the dipolar interaction between host nuclear spins and impurity
spins, a nonuniform distribution in the host nuclear spin system will occur and
consequently the macroscopic relaxation time will be strongly determined by the
spin diffusion. The explicit expressions for the relaxation time in certain
physically relevant cases are given.Comment: 41 pages, 119 Refs. Corrected typos, added reference
A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials
BACKGROUND: When rates of uptake of other drugs differ between treatment arms in long-term trials, the true benefit or harm of the treatment may be underestimated. Methods to allow for such contamination have often been limited by failing to preserve the randomization comparisons. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, patients were randomized to fenofibrate or placebo, but during the trial many started additional drugs, particularly statins, more so in the placebo group. The effects of fenofibrate estimated by intention-to-treat were likely to have been attenuated. We aimed to quantify this effect and to develop a method for use in other long-term trials. METHODOLOGY/PRINCIPAL FINDINGS: We applied efficacies of statins and other cardiovascular drugs from meta-analyses of randomized trials to adjust the effect of fenofibrate in a penalized Cox model. We assumed that future cardiovascular disease events were reduced by an average of 24% by statins, and 20% by a first other major cardiovascular drug. We applied these estimates to each patient who took these drugs for the period they were on them. We also adjusted the analysis by the rate of discontinuing fenofibrate. Among 4,900 placebo patients, average statin use was 16% over five years. Among 4,895 assigned fenofibrate, statin use was 8% and nonuse of fenofibrate was 10%. In placebo patients, use of cardiovascular drugs was 1% to 3% higher. Before adjustment, fenofibrate was associated with an 11% reduction in coronary events (coronary heart disease death or myocardial infarction) (P = 0.16) and an 11% reduction in cardiovascular disease events (P = 0.04). After adjustment, the effects of fenofibrate on coronary events and cardiovascular disease events were 16% (P = 0.06) and 15% (P = 0.008), respectively. CONCLUSIONS/SIGNIFICANCE: This novel application of a penalized Cox model for adjustment of a trial estimate of treatment efficacy incorporates evidence-based estimates for other therapies, preserves comparisons between the randomized groups, and is applicable to other long-term trials. In the FIELD study example, the effects of fenofibrate on the risks of coronary heart disease and cardiovascular disease events were underestimated by up to one-third in the original analysis. TRIAL REGISTRATION: Controlled-Trials.com ISRCTN64783481
Elevated Expression of Phospholipid Transfer Protein in Bone Marrow Derived Cells Causes Atherosclerosis
Background: Phospholipid transfer protein (PLTP) is expressed by various cell types. In plasma, it is associated with high density lipoproteins (HDL). Elevated levels of PLTP in transgenic mice result in decreased HDL and increased atherosclerosis. PLTP is present in human atherosclerosis lesions, where it seems to be macrophage derived. The aim of the present study is to evaluate the atherogenic potential of macrophage derived PLTP. Methods and Findings: Here we show that macrophages from human PLTP transgenic mice secrete active PLTP. Subsequently, we performed bone marrow transplantations using either wild type mice (PLTPwt/wt), hemizygous PLTP transgenic mice (huPLTPtg/wt) or homozygous PLTP transgenic mice (huPLTPtg/tg) as donors and low density lipoprotein receptor deficient mice (LDLR-/-) as acceptors, in order to establish the role of PLTP expressed by bone marrow derived cells in diet-induced atherogenesis. Atherosclerosis was increased in the huPLTPtg/wt → LDLR-/ - mice (2.3-fold) and even further in the huPLTPtg/tg→LDLR-/ - mice (4.5-fold) compared with the control PLTPwt/wt→LDLR-/- mice (both P<0.001). Plasma PLTP activity levels and non-HDL cholesterol were increased and HDL cholesterol decreased compared with controls (all P<0.01). PLTP was present in atherosclerotic plaques in the mice as demonstrated by immunohistochemistry and appears to co-localize with macrophages. Isolated macrophages from PLTP transgenic mice do not show differences in cholesterol efflux or in cytokine production. Lipopolysaccharide activation of macrophages results in increased production of PLTP. This effect was strongly amplified in PLTP transgenic macrophages. Conclusions: We conclude that PLTP expression by bone marrow derived cells results in atherogenic effects on plasma lipids, increased PLTP activity, high local PLTP protein levels in the atherosclerotic lesions and increased atherosclerotic lesion size
- …